MoonLake Immunotherapeutics (MLTX) Operating Expenses (2021 - 2026)

MoonLake Immunotherapeutics' Operating Expenses history runs 6 years deep, the most recent figure standing at $70.0 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 47.47% year-over-year to $70.0 million; the TTM figure through Mar 2026 stood at $267.4 million (up 56.58% YoY), while the FY2025 annual figure was $244.8 million, up 71.1% from the prior year.
• Operating Expenses was $70.0 million for Q1 2026 at MoonLake Immunotherapeutics, up from $65.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $71.4 million in Q3 2025 to a low of $12.9 million in Q1 2023.
• Historically, Operating Expenses has averaged $33.9 million across 5 years, with a median of $19.8 million in 2024.
• Biggest YoY gain for Operating Expenses was 16840.81% in 2022; the steepest drop was 68.84% in 2022.
• A 5-year view of Operating Expenses shows it stood at $16.7 million in 2022, then dropped by 9.99% to $15.0 million in 2023, then jumped by 229.9% to $49.6 million in 2024, then soared by 31.54% to $65.2 million in 2025, then gained by 7.37% to $70.0 million in 2026.
• The last three Operating Expenses figures came in at $70.0 million (Q1 2026), $65.2 million (Q4 2025), and $71.4 million (Q3 2025), per Business Quant data.